RNAimmune gets $2.35M for mRNA therapeutics, vaccines
RNAimmune has secured $2.35 million in seed round financing from multiple venture capital firms to advance its COVID-19 vaccine RV1730 program and neoantigen-based cancer vaccine programs. Read More
Novavax begins phase II trial of COVID-19 vaccine
Novavax has dosed the first participants in a phase II portion of an ongoing clinical trial to investigate the immunogenicity and safety of NVX-CoV2373, the company's SARS-CoV-2 vaccine candidate. Read More
Moderna discusses supplying 80M doses of mRNA-1273 to EU
Moderna is in discussions with the European Commission to supply 80 million doses of messenger RNA (mRNA)-1273, Moderna's COVID-19 vaccine candidate, as part of the commission's goal to secure early access to safe and effective COVID-19 vaccines for Europe. Read More
Avid Bioservices to manufacture Oragenics coronavirus vaccine
Avid Bioservices and Oragenics have signed an agreement to accelerate the development of a vaccine against COVID-19. Read More
IsoPlexis, Lonza partner on cell therapy manufacturing
IsoPlexis and Lonza have partnered to advance automated cell therapy manufacturing. Read More
Adaptive Phage gets $10M to develop COVID-19 vaccine
Adaptive Phage Therapeutics has been awarded $9.8 million by the U.S. Department of Defense to develop multiple high-priority bacteriophage-based display vaccine candidates against SARS-CoV-2. Read More
J&J to acquire Momenta for $6.5B
Johnson & Johnson has entered an agreement to acquire Momenta Pharmaceuticals in an all-cash transaction for approximately $6.5 billion with a tender offer to purchase all outstanding shares of Momenta for $52.50 per share. Read More
Thermo Fisher debuts hematology/oncology assays
Thermo Fisher Scientific has debuted hematology/oncology assays that enable simultaneous analysis of DNA mutations and RNA fusion transcripts in myeloid samples in a day. Read More
Fujifilm Diosynth breaks ground on biologics facility
Fujifilm Diosynth Biotechnologies, a contract development and manufacturing organization for biologics, viral vaccines, and gene therapies, held a virtual groundbreaking ceremony on August 19 for its Advanced Therapies Innovation Center construction project in Texas. Read More
News report highlights risk of infectious disease research
Incidents with exposure to lab-created coronaviruses highlight the risks of working with pathogens, even in highly secure research facilities, according to an article published in ProPublica on August 17. Read More
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
